Appointments
+(603) 5515 1966
General Line
+(603) 5515 1888
March 7, 2025
Gestational Trophoblastic Disease refers to a rare group of tumours that involve abnormal growth of cells inside a woman’s uterus after conception. This group includes both benign and malignant conditions.
It is a unique disease because, unlike other cancers, it originates from pregnancy tissue rather than the body’s own cells. Gestational Trophoblastic Disease can be life-threatening if left untreated, yet it is highly treatable in most cases with early diagnosis.
GTD or Gestational Trophoblastic Disease encompasses a spectrum of conditions characterised by abnormal growth of the trophoblast, a layer of cells that surrounds the fertilised egg and helps form the placenta. It can be classified into two main categories:
Benign GTD which includes hydatidiform moles, commonly referred to as molar pregnancies.
Malignant GTD which includes conditions such as:
Recognising the symptoms of gestational trophoblastic disease is vital for early intervention. Common symptoms include:
Gestational Trophoblastic Disease originates primarily from abnormal fertilisation events and other risk-enhancing factors. Here’s a detailed breakdown of the causes:
GTD is caused by chromosomal imbalances during fertilisation. Complete Molar Pregnancy happens when an empty egg is fertilised by a sperm, leading to abnormal placental tissue and no foetal development. Partial Molar Pregnancy occurs when a normal egg is fertilised by two sperm, resulting in abnormal foetus and placental tissue. These chromosomal errors cause the trophoblastic cells to grow uncontrollably, leading to Gestational Trophoblastic Disease.
Some women are more likely to develop GTD due to factors such as maternal age (risk increases for women under 20 or over 40), history of molar pregnancy (increases chances of recurrence), and miscarriage/infertility history (slightly higher risk for those with recurrent pregnancy loss or trouble conceiving).
A lack of vitamin A and beta-carotene in the diet has been linked to the development of gestational trophoblastic disease. In areas with high GTD rates like Southeast Asia and sub-Saharan Africa, poor intake of micronutrients may increase the risk of developing the condition.
The occurrence of gestational trophoblastic disease differs by region and ethnicity, with higher rates found in Asia, Latin America, and Africa. Factors like culture, environment, and diet may contribute to the increased risk in these areas. Limited access to healthcare and prenatal screening could delay detection and treatment. Additionally, certain ethnic groups, such as Asian women, may have a slightly higher risk due to genetic or environmental influences.
Some cases of gestational trophoblastic disease can be caused by unusual reproductive factors, such as pregnancies resulting from in vitro fertilization (IVF) or other fertility treatments, as well as uterine abnormalities or genetic predispositions.
Diagnosing Gestational Trophoblastic Disease involves a combination of clinical evaluation, laboratory tests, and imaging studies. Early and accurate diagnosis is crucial for appropriate treatment and monitoring, especially given the potential for malignancy in some forms of GTD. Below is a detailed exploration of the diagnostic process:
The diagnostic journey often begins with a review of the patient’s symptoms, such as abnormal vaginal bleeding, severe nausea, and rapid uterine growth. A detailed pregnancy history, including prior molar pregnancies or miscarriages, can provide important clues. An enlarged uterus disproportionate to gestational age or palpable masses may suggest abnormal growth of trophoblastic tissue.
Human chorionic gonadotropin (HCG) is a hormone produced by trophoblastic cells during pregnancy. Abnormally high or persistently elevated HCG levels are a hallmark of Gestational Trophoblastic Disease.
In a normal pregnancy, HCG levels rise and plateau at predictable rates. In Gestational Trophoblastic Disease, levels often skyrocket beyond expected ranges or fail to decline after a pregnancy event (miscarriage or delivery).
Ultrasound is the main imaging technique used to diagnose GTD. This condition is identified by a distinct “snowstorm” or “cluster of grapes” pattern on ultrasound, which signifies the lack of foetal structures and the presence of cystic placental tissue. This imaging method reveals a combination of abnormal placental tissue and a deformed foetus, aiding in the differentiation of GTD from other pregnancy complications such as missed miscarriage or ectopic pregnancy.
After uterine evacuation, a sample of the abnormal tissue is sent for histopathological examination. This analysis confirms the diagnosis by identifying characteristic features of molar pregnancies or malignant GTD. Features such as swollen chorionic villi, absence of foetal vessels, or invasive trophoblastic tissue provide a definitive diagnosis.
In cases of suspected malignant GTD, imaging studies assess the spread of the disease.
These modalities are reserved for high-risk patients or those with atypical symptoms, such as neurological deficits or persistent chest pain.
May be used to assess blood flow in trophoblastic tissue, aiding in the diagnosis of vascular tumours like choriocarcinoma.
Additional bloodwork, including complete blood count (CBC) and liver and kidney function tests, helps assess overall health and rule out complications.
Early detection of Gestational Trophoblastic Disease not only ensures effective treatment but also minimises complications, especially in malignant cases. Women experiencing abnormal pregnancy symptoms should seek immediate medical attention to facilitate prompt evaluation and intervention.
By combining clinical expertise with advanced diagnostic technologies, healthcare providers can ensure accurate identification and timely management of this rare but significant condition.
Treatment of GTD depends on the specific type, its extent and whether it has spread (metastasised). The main types of GTD include hydatidiform mole (complete or partial), invasive mole, choriocarcinoma, and placental-site trophoblastic tumours (PSTTs).
Suction Curettage (D&C) is the primary treatment for hydatidiform moles, involving the removal of the mole from the uterus through suction and curettage. Hysterectomy is an option for women who no longer desire to preserve fertility, particularly in cases of invasive mole or placental-site trophoblastic tumours.
Single-agent chemotherapy, such as methotrexate or dactinomycin, is frequently successful in treating low-risk gestational trophoblastic disease. On the other hand, combination chemotherapy, like EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine), is utilised for high-risk cases. This treatment has shown to be particularly effective for metastatic GTD, particularly choriocarcinoma. The response to chemotherapy is carefully monitored by tracking serial beta-HCG (human chorionic gonadotropin) levels.
It is important to regularly monitor HCG levels after treatment to confirm the eradication of the disease. An increase in HCG levels could suggest the presence of persistent GTD or a recurrence. Additional imaging tests such as ultrasound, CT scans, or MRI may be utilised to identify any remaining or spreading disease.
Rarely used but may be considered for metastatic GTD involving the brain or other distant organs.
In cases of resistant or recurrent gestational trophoblastic disease (GTD), patients may consider experimental treatments or targeted therapies as potential options.
Emotional support and counselling, as GTD can be a distressing diagnosis. Fertility preservation discussions for patients undergoing treatment.
The prognosis for gestational trophoblastic disease is generally excellent, particularly with early detection and appropriate treatment. Most cases, especially hydatidiform moles and low-risk GTD respond well to surgical removal and, if necessary, chemotherapy. Cure rates exceed 90-95% for non-metastatic and low-risk metastatic GTD. Even in high-risk or metastatic cases, advances in combination chemotherapy have significantly improved survival rates. Long-term outcomes for fertility are favourable for most patients, allowing normal pregnancies after treatment.
However, patients must adhere to long-term follow-up, including regular monitoring of beta-HCG levels, to detect any recurrence early. With proper care, the risk of recurrence is low, and most women experience full recovery.
For people suffering from the disease, coping with the diagnosis and treatment is can be challenging. Seek support from family, friends, or support groups to cope with feelings of anxiety, sadness, or grief. Consider counselling or therapy for emotional well-being.
Another important aspect is learning about GTD, its treatment, and recovery to reduce fear and uncertainty. Ask your healthcare provider questions and stay informed about your condition. Connect with others who have experienced GTD through online or local support groups. Sharing experiences can help alleviate isolation and provide coping strategies.
Discuss future family planning and fertility concerns with your doctor to prepare for a healthy pregnancy post-recovery. Follow medical advice on when it is safe to conceive again. Eat a balanced diet and engage in light physical activity as recommended by your doctor to support recovery. Avoid pregnancy for the advised duration to allow full healing and monitoring.
Currently, there is no known way to prevent gestational trophoblastic disease, as the exact causes remain unclear. However, certain steps can help reduce the risk or ensure early detection:
Gestational Trophoblastic Disease, though rare, underscores the importance of early detection and specialised care. Awareness of gestational trophoblastic disease symptoms, understanding the gestational trophoblastic disease causes, and seeking prompt medical attention can make a significant difference. With advances in the treatment of GTD, the prognosis is often excellent, enabling women to lead healthy, fulfilling lives post-recovery. By fostering education and support, we can ensure that no woman faces this journey alone.
If you suspect symptoms or have a history of GTD, consult your healthcare provider for guidance and timely intervention.
Gestational Trophoblastic Disease is a rare group of pregnancy-related conditions where abnormal cells grow in the tissue that would normally develop into the placenta.
A hydatidiform mole is a type of gestational trophoblastic disease, which encompasses a broader group of abnormal placental tissue growths, including more invasive and malignant forms.
Symptoms of trophoblastic disease include abnormal vaginal bleeding, high HCG levels, pelvic pain, and excessive nausea or vomiting during pregnancy.
In gestational trophoblastic disease, HCG levels are abnormally high and often exceed normal pregnancy ranges, reflecting the excessive growth of trophoblastic tissue.
Sources:
Spread the love, follow us on our social media channels